Vedanta Biosciences Inc. v. Seres Therapeutics, Inc.
1:24-cv-00957
Overview
Parties
Defendant
Nestle HealthCare Nutrition, Inc. Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Aimmune Therapeutics, Inc. Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
NHSc RX License GmbH Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Nestle Health Science US Holdings, Inc. NPE (Patent Assertion Entity)
Represented By
0 Attorneys ListedNestle Health Science S.A. Operating Company
Represented By
0 Attorneys ListedSociete des Produits Nestle S.A. Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Nestle S.A. NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Seres Therapeutics, Inc. Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
The University of Tokyo NPE (University / Research)
Represented By
5 Attorneys ListedVenable LLP
1201 N. Market Street, Suite 1400, Wilmington, DE 19801
Greenberg Traurig, LLP
222 Delaware Avenue, Suite 1600
Vedanta Biosciences Inc. Operating Company
Represented By
5 Attorneys ListedVenable LLP
1201 N. Market Street, Suite 1400, Wilmington, DE 19801
Greenberg Traurig, LLP
222 Delaware Avenue, Suite 1600
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 24 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9433652
Composition for inducing proliferation or accumulation of regulatory T cells
|
Filed: 2014-09-22
Issued: 2016-09-06
|
Active (4.7 yrs remaining)
Expires: 2031-08-16
|
|
|
US9662381
Composition for inducing proliferation or accumulation of regulatory T cells
|
Filed: 2016-12-09
Issued: 2017-05-30
|
Active (10.1 yrs remaining)
Expires: 2036-12-09
|
|
|
US9808519
Composition for inducing proliferation or accumulation of regulatory T cells
|
Filed: 2017-05-09
Issued: 2017-11-07
|
Active (10.5 yrs remaining)
Expires: 2037-05-09
|
|
|
US10555978
Composition for inducing proliferation or accumulation of regulatory T cells
|
Filed: 2019-05-29
Issued: 2020-02-11
|
Active (12.5 yrs remaining)
Expires: 2039-05-29
|
|
|
US11090343
Composition for inducing proliferation or accumulation of regulatory T cells
|
Filed: 2020-02-03
Issued: 2021-08-17
|
Active (13.2 yrs remaining)
Expires: 2040-02-03
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
23
Dispositive
19
Granted
1
Denied
1
Pending / Review
19
Motions by Category
Key Dispositive Motions & Rulings